Analyst Activity – Royal Bank Of Canada Reiterates Hold on Novelion Therapeutics (NASDAQ:NVLN)

ME Staff
-
0

Analyst Ratings For Novelion Therapeutics (NASDAQ:NVLN)

Today, Royal Bank Of Canada reiterated its Hold rating on Novelion Therapeutics (NASDAQ:NVLN) with a price target of $9.00.

There are 2 hold ratings on the stock.

The current consensus rating on Novelion Therapeutics (NASDAQ:NVLN) is Hold (Score: 2.00) with a consensus target price of $9.00 per share, a potential 25.70% upside.

Some recent analyst ratings include

  • 10/3/2017-Royal Bank Of Canada Reiterated Rating of Hold.
  • 6/19/2017-Bloom Burton Reiterated Rating of Accumulate.
  • 10/30/2015-Roth Capital Reiterated Rating of Buy.

Recent Insider Trading Activity For Novelion Therapeutics (NASDAQ:NVLN)
Novelion Therapeutics (NASDAQ:NVLN) has insider ownership of 14.10% and institutional ownership of 78.44%.

  • On 6/12/2017 Donald K Stern, Director, bought 2,500 with an average share price of $9.10 per share and the total transaction amounting to $22,750.00. View SEC Filing
  • On 5/15/2017 Jason Aryeh, Director, bought 361 with an average share price of $8.95 per share and the total transaction amounting to $3,230.95. View SEC Filing
  • On 9/15/2016 Stonepine Capital, L.P., Major Shareholder, bought 133,496 with an average share price of $1.55 per share and the total transaction amounting to $206,918.80. View SEC Filing
  • On 12/29/2015 Jason Aryeh, Director, bought 18,400 with an average share price of $2.50 per share and the total transaction amounting to $46,000.00. View SEC Filing
  • On 6/16/2015 Axial Capital Master, L.P., Major Shareholder, sold 7,563,053 with an average share price of $3.47 per share and the total transaction amounting to $26,243,793.91. View SEC Filing
  • On 6/16/2015 Jason Aryeh, Director, bought 288,000 with an average share price of $3.47 per share and the total transaction amounting to $999,360.00. View SEC Filing
  • On 12/22/2014 John W Kozarich, Director, bought 10,000 with an average share price of $3.59 per share and the total transaction amounting to $35,900.00. View SEC Filing

Recent Trading Activity for Novelion Therapeutics (NASDAQ:NVLN)
Shares of Novelion Therapeutics closed the previous trading session at with shares trading hands.